Table 3.

Pharmacokinetic Parameters of Gallic Acid (GA) and Gallic acid Nanocomposite (GA-NC) in Normal and Hepatocellular Carcinoma (HCC)-induced Rats

	GA (50 mg/kg) in normal rats	GA (50 mg/kg) in HCC-afflicted rats	GA-NC (50 mg/kg) in normal rats	GA-NC (50 mg/kg) in HCC-afflicted rats
C max (µg/ml)	1.57 ± 0.108	0.923a±0.33	2.45a ±0.07	2.62a±0.18
T max (h)	0.46±0.085	0.87a±0.25	0.625±0.125	2.00a, b±0.0
T 1/2 (h)	0.62±0.09	1.14a± 0.32	1.22a±0.15	2.09a, b±0.02
AUClast (µg.ml.h-1)	1.641±0.045	1.34±0.194	6.25a±0.188	7.3a, b±0.8
AUC (µg.ml.h-1)	1.89±0.13	1.67±0.04	6.52a±0.31	7.52a, b±0.8
AUMC last (µg.ml.h-1)	1.3±0.13	1.55±0.014	11.29a±1.66	13.56a, b±1.6
AUMC (µg.ml.h-1)	2.03±0.44	1.55±0.014	13.36a±2.7	14.65a±1.6
MRT (h)	1.063±0.155	1.43±0.34	2.037a±0.322	1.96a±0.03

^asignificantly different from GA in normal rats,

^bsignificantly different from GA-NC in normal rats,

^csignificantly different from GA in HCC-afflicted rats